What is Zacks Small Cap’s Forecast for LEXX Q4 Earnings?

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Zacks Small Cap issued their Q4 2025 earnings estimates for shares of Lexaria Bioscience in a report issued on Tuesday, January 28th. Zacks Small Cap analyst J. Vandermosten anticipates that the company will earn ($0.13) per share for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.42) per share. Zacks Small Cap also issued estimates for Lexaria Bioscience’s FY2027 earnings at ($0.38) EPS.

Lexaria Bioscience (NASDAQ:LEXX) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Lexaria Bioscience had a negative net margin of 1,473.04% and a negative return on equity of 88.88%.

Separately, HC Wainwright cut their price target on Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, January 24th.

Lexaria Bioscience Trading Down 1.2 %

Shares of LEXX opened at $1.71 on Wednesday. The business’s fifty day moving average price is $2.15 and its two-hundred day moving average price is $2.71. Lexaria Bioscience has a 52 week low of $1.42 and a 52 week high of $6.85.

Hedge Funds Weigh In On Lexaria Bioscience

Several hedge funds have recently added to or reduced their stakes in the stock. Byrne Asset Management LLC increased its stake in shares of Lexaria Bioscience by 132.1% in the 4th quarter. Byrne Asset Management LLC now owns 13,000 shares of the company’s stock valued at $27,000 after acquiring an additional 7,400 shares during the last quarter. HighTower Advisors LLC bought a new stake in Lexaria Bioscience in the third quarter valued at approximately $40,000. XTX Topco Ltd raised its holdings in Lexaria Bioscience by 47.8% in the third quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock worth $57,000 after purchasing an additional 6,024 shares during the period. Renaissance Technologies LLC acquired a new stake in Lexaria Bioscience in the second quarter worth $63,000. Finally, Geode Capital Management LLC boosted its position in shares of Lexaria Bioscience by 31.0% during the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock worth $459,000 after purchasing an additional 35,608 shares in the last quarter. Institutional investors and hedge funds own 13.06% of the company’s stock.

Insider Buying and Selling

In related news, CEO Richard Christopher purchased 22,828 shares of Lexaria Bioscience stock in a transaction dated Monday, December 2nd. The shares were acquired at an average cost of $2.24 per share, for a total transaction of $51,134.72. Following the transaction, the chief executive officer now directly owns 22,828 shares of the company’s stock, valued at approximately $51,134.72. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 26.40% of the stock is currently owned by insiders.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.